Show Summary Details
Page of

The Role of Cytotoxic Chemotherapy in Melanoma 

The Role of Cytotoxic Chemotherapy in Melanoma
The Role of Cytotoxic Chemotherapy in Melanoma

Adil Daud

and Michelle Ashworth

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 July 2020

Advanced (unresectable stage III, metastatic stage IV) melanoma is often described as being resistant to cytotoxic chemotherapy, with low objective response (complete response + partial response) rates across regimens in various melanoma subtypes (cutaneous, mucosal, or uveal). As a result, chemotherapy in such cases has been largely palliative. Occasionally, however, a complete response occurs, or a deep partial response can be followed by metastectomy and lead to prolonged disease-free survival. This chapter focuses largely on the response rate and overall survival benefit offered by selected regimens, provides a brief historic overview of regimens evaluated in advanced melanoma, and concludes with a discussion of regimens commonly in use today.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.